AbbVie Inc
ABBV222.000USD
+1.190+0.54%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
392.15BMarket Cap
105.33P/E TTM
More Details of AbbVie Inc Company
AbbVie Inc. is an American pharmaceutical firm based in North Chicago, Illinois. Its prominent products include Humira, which is approved for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis, and is administered through injection; Skyrizi, an interleukin-23 inhibitor also aimed at treating autoimmune disorders; Rinvoq, utilized for arthritis management; and Botox. Other significant offerings comprise Imbruvica for cancer treatment, Vraylar for schizophrenia and bipolar disorder, Venclexta for leukemia and lymphoma, and Mavyret for Hepatitis C treatment. The company is also dedicated to advancing therapies for additional conditions such as cancer, neurologic diseases, eye care, and cystic fibrosis.
AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.
The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'
Company Info
Ticker SymbolABBV
Company nameAbbVie Inc
IPO dateJan 02, 2013
CEOMr. Robert A. Michael, CPA
Number of employees55000
Security typeOrdinary Share
Fiscal year-endJan 02
Address1 N Waukegan Rd
CityNORTH CHICAGO
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code60064
Phone18479327900
Websitehttps://www.abbvie.com/
Ticker SymbolABBV
IPO dateJan 02, 2013
CEOMr. Robert A. Michael, CPA
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
--
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.90%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.88%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
+3.23%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
+3.49%
Mr. Frederick H. (Rick) Waddell
Mr. Frederick H. (Rick) Waddell
Independent Director
Independent Director
28.96K
+4.33%
Ms. Melody B. Meyer
Ms. Melody B. Meyer
Independent Director
Independent Director
16.50K
+7.87%
Mr. Timothy J. Richmond
Mr. Timothy J. Richmond
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
6.13K
-77.61%
Ms. Jennifer L. Davis
Ms. Jennifer L. Davis
Independent Director
Independent Director
2.52K
+91.00%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
--
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.90%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.88%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
+3.23%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
+3.49%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Immunology-SKYRIZI
3.42B
25.21%
Immunology-RINVOQ
1.72B
12.64%
Immunology-HUMIRA
1.12B
8.25%
Hematologic Oncology-IMBRUVICA
947.00M
6.97%
Neuroscience-Botox Therapeutic
866.00M
6.37%
Other
5.51B
40.56%
By RegionUSD
Name
Revenue
Proportion
United States
9.39B
69.13%
International
3.20B
23.56%
All other countries
747.00M
5.50%
Collaboration revenue
245.00M
1.80%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Immunology-SKYRIZI
3.42B
25.21%
Immunology-RINVOQ
1.72B
12.64%
Immunology-HUMIRA
1.12B
8.25%
Hematologic Oncology-IMBRUVICA
947.00M
6.97%
Neuroscience-Botox Therapeutic
866.00M
6.37%
Other
5.51B
40.56%
Shareholding Stats
Updated: Sun, Aug 17
Updated: Sun, Aug 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.99%
BlackRock Institutional Trust Company, N.A.
5.21%
State Street Global Advisors (US)
4.53%
Geode Capital Management, L.L.C.
2.22%
JP Morgan Asset Management
2.12%
Other
75.93%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.99%
BlackRock Institutional Trust Company, N.A.
5.21%
State Street Global Advisors (US)
4.53%
Geode Capital Management, L.L.C.
2.22%
JP Morgan Asset Management
2.12%
Other
75.93%
Shareholder Types
Shareholders
Proportion
Investment Advisor
43.57%
Investment Advisor/Hedge Fund
19.92%
Research Firm
3.07%
Bank and Trust
2.29%
Pension Fund
2.19%
Sovereign Wealth Fund
1.40%
Hedge Fund
1.28%
Insurance Company
0.68%
Family Office
0.20%
Other
25.39%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
5271
1.32B
74.93%
+10.38M
2025Q1
5332
1.32B
74.90%
+11.71M
2024Q4
5219
1.31B
74.47%
+8.91M
2024Q3
4974
1.30B
73.54%
-7.44M
2024Q2
4916
1.30B
73.53%
+2.27M
2024Q1
4930
1.29B
72.58%
-1.47M
2023Q4
4882
1.28B
72.31%
-1.48M
2023Q3
4694
1.27B
71.87%
-12.06M
2023Q2
4688
1.26B
71.51%
-30.42M
2023Q1
4658
1.27B
71.97%
-18.58M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
177.27M
10.04%
+4.12M
+2.38%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
91.03M
5.15%
+950.86K
+1.06%
Mar 31, 2025
State Street Global Advisors (US)
79.96M
4.53%
+341.48K
+0.43%
Mar 31, 2025
Geode Capital Management, L.L.C.
38.25M
2.17%
+1.11M
+2.98%
Mar 31, 2025
JP Morgan Asset Management
35.61M
2.02%
+1.70M
+5.02%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
25.27M
1.43%
-2.17M
-7.91%
Mar 31, 2025
Capital Research Global Investors
33.51M
1.9%
-475.69K
-1.40%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
23.25M
1.32%
+571.37K
+2.52%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
25.10M
1.42%
+2.62M
+11.64%
Dec 31, 2024
Fidelity Management & Research Company LLC
21.43M
1.21%
+4.44M
+26.15%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Direxion Daily Healthcare Bull 3X Shares
5.47%
Bahl & Gaynor Dividend ETF
2.85%
Capital Group Conservative Equity ETF
1.81%
PIMCO RAFI ESG US ETF
1.67%
Franklin US Large Cap Multifactor Index ETF (US)
1.63%
ALPS O'Shares US Quality Dividend ETF
1.1%
Stance Sustainable Beta ETF
1.04%
iShares Climate Conscious & Transtn MSCI USA ETF
0.91%
Franklin US Equity Index ETF
0.69%
Columbia Research Enhanced Core ETF
0.69%
View more
Direxion Daily Healthcare Bull 3X Shares
Proportion5.47%
Bahl & Gaynor Dividend ETF
Proportion2.85%
Capital Group Conservative Equity ETF
Proportion1.81%
PIMCO RAFI ESG US ETF
Proportion1.67%
Franklin US Large Cap Multifactor Index ETF (US)
Proportion1.63%
ALPS O'Shares US Quality Dividend ETF
Proportion1.1%
Stance Sustainable Beta ETF
Proportion1.04%
iShares Climate Conscious & Transtn MSCI USA ETF
Proportion0.91%
Franklin US Equity Index ETF
Proportion0.69%
Columbia Research Enhanced Core ETF
Proportion0.69%
Dividend
A total of
48.58B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 06, 2024
ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 21, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 15, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Oct 27, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option
Jan 16, 2024
Feb 15, 2024
Jan 12, 2024
Sep 11, 2023
ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option
Oct 13, 2023
Nov 15, 2023
Oct 12, 2023
Jun 22, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option
Jul 14, 2023
Aug 15, 2023
Jul 13, 2023
Feb 16, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option
Apr 14, 2023
May 15, 2023
Apr 13, 2023
Oct 28, 2022
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option
Jan 13, 2023
Feb 15, 2023
Jan 12, 2023
Sep 09, 2022
ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option
Oct 14, 2022
Nov 15, 2022
Oct 13, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
